Please assess the completion status of the following clinical trial:

Trial Title: Imaging of Osteonecrosis With Ferumoxytol-Enhanced MRI

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: FACTORIAL
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Osteonecrosis~* planned decompression surgery with autologous stem cell transplant~Exclusion Criteria:~* Contraindications for magnetic resonance imaging~* Hemosiderosis/hemochromatosis ( patients can still be included in the non-ferumoxytol arm)

- Gender: ALL
- Minimum Age: 8 Years
- Maximum Age: 40 Years
- Healthy Volunteers: f

Study Arms:
- Ferumoxytol-enhanced MRI (Type: ACTIVE_COMPARATOR): Patients receive a ferumoxytol injection (Feraheme, AMAG, 5mg Fe/kg, single administration) prior to routine decompression surgery and autologous stem cell transplant. Follow-up imaging with magnetic resonance imaging will be conducted in regular intervals for evaluation of the response to treatment.
- Non-ferumoxytol enhanced MRI (Type: SHAM_COMPARATOR): Patients scheduled for routine decompression surgery and autologous stem cell transplant will receive follow-up magnetic resonance imaging in regular intervals for evaluation of the response to treatment.

Based on this trial design, predict the completion outcome and termination type (if applicable).